Loading clinical trials...
Loading clinical trials...
A Phase 1, 2-Part, Open-Label, Single-Dose, Parallel Group Study to Determine the Effect of Hepatic Impairment on the Safety, Tolerability, and Pharmacokinetics of ACH-0144471 in Adult Subjects
Conditions
Interventions
Danicopan
Locations
2
United States
Clinical Trial Site
Miami, Florida, United States
Clinical Trial Site
Orlando, Florida, United States
Start Date
May 1, 2018
Primary Completion Date
September 21, 2018
Completion Date
September 21, 2018
Last Updated
August 20, 2021
NCT07324616
NCT04271488
NCT06952634
NCT06841315
NCT06619054
NCT06813781
Lead Sponsor
Alexion Pharmaceuticals, Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions